Sildenafil citrate

CHF 60.00
In stock
SYN-3016-M0011 mgCHF 60.00
SYN-3016-M0055 mgCHF 132.00
SYN-3016-M01010 mgCHF 239.00
SYN-3016-M05050 mgCHF 329.00
SYN-3016-M100100 mgCHF 515.00
 
More Information
Product Details
Synonyms Viagra; Revatio
Product Type Chemical
Properties
Formula C22H30N6O4S . C6H8O7
MW 474.6 . 192.1
CAS 171599-83-0
Purity Chemicals ≥95%
Appearance Solid.
Solubility Soluble in DMSO or ethanol.
Declaration Manufactured by SynKinase.
Other Product Data Target: PDE5 | Kinase Group: N/A | Substrate: N/A

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key DEIYFTQMQPDXOT-UHFFFAOYSA-N
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Sildenafil citrate is an orally active selective inhibitor of cGMP-specific PDE5 (phosphodiesterase type 5), an enzyme that regulates blood flow in the penis and which is the predominant PDE isoenzyme in human corpora cavernosa. Sildenafil citrate is used as an agent to treat erectile dysfunction and pulmonary arterial hypertension (PAH). Studies in vitro have shown that sildenafil has between 10 and 10,000-fold greater selectivity for PDE5 than for other phosphodiesterase isoforms (PDEs 1, 2, 3, 4, 6, 7 to 11). In particular, sildenafil has greater than 4,000-fold selectivity for PDE5 over PDE3, the cAMP-specific phosphodiesterase isoform involved in the control of cardiac contractility. Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 (IC50 >150 mM).
Product References
  1. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes: S.A. Ballard, et al.; J. Urol. 159, 2164 (1998)
  2. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds: I.V. Turko, et al.; Mol. Pharmacol. 56, 124 (1999)
  3. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond: H.A. Ghofrani, et al.; Nat. Rev. Drug Discov. 5, 689 (2006)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.